Cataplexy Pipeline Analysis, 2025 by DelveInsight | Avadel, Axome Therapeutics

DelveInsight's, "Cataplexy - Pipeline Insight, 2025," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cataplexy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, over three key companies are actively advancing more than three therapies for the treatment of cataplexy.

DelveInsight's "Cataplexy - Pipeline Insight, 2025" offers a concise overview of the current pipeline landscape and future growth potential in cataplexy. The report covers disease background, treatment guidelines, and a comprehensive analysis of pipeline candidates, including their mechanisms, clinical progress, and development updates such as collaborations, funding, and designations.

Request for a detailed cataplexy pipeline analysis report @ https://www.delveinsight.com/report-store/cataplexy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key Takeaways from the cataplexy Pipeline Report:

*
DelveInsight's analysis of the cataplexy pipeline reveals a dynamic landscape, with more than three active companies developing over three investigational therapies across different stages of clinical development.

*
In December 2024, the FDA granted de novo classification and market authorization to ONWARD Medical's ARC-EX system. This non-invasive spinal cord stimulation device is the first approved to enhance hand strength and sensation in individuals with chronic cataplexy, with clinical trials showing that 72% of participants experienced improved hand function and sensory perception.

*
Earlier, in May 2024, the FDA approved Abbott's suite of Spinal Cord Stimulation (SCS) systems, including Prodigy, Proclaim Plus, Proclaim XR, and Eterna. These implantable neurostimulators are designed to alleviate chronic pain in the torso, arms, and legs, providing relief for patients with intractable pain conditions.

*
Leading companies such as Avadel, Axome Therapeutics, and others are actively evaluating new therapies to expand treatment options for cataplexy. Notable pipeline candidates in various stages of development include FT218, AXS12, among others.

Cataplexy Overview

Cataplexy is characterized by brief episodes of muscle weakness triggered by strong emotions, particularly positive ones such as laughter or excitement. These sudden attacks, lasting from a few seconds to several minutes, involve partial or complete paralysis of voluntary muscles, while muscles controlling eye movement and breathing remain functional. The condition is associated with the inhibition of serotonergic and noradrenergic neural pathways, which underlies the temporary muscle paralysis seen during cataplectic episodes.

Uncover the latest breakthroughs in cataplexy therapeutics, download our report @ https://www.delveinsight.com/sample-request/cataplexy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Cataplexy Pipeline Analysis

The cataplexy pipeline insights report 2025 provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the cataplexy Market.

*
Categorizes cataplexy therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging cataplexy drugs under development based on:

*
Stage of development

*
cataplexy Route of Administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
cataplexy Mechanism of Action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
cataplexy Licensing Agreements

*
Funding and investment activities that support future advancements in the cataplexy market.

Get Full Insights into the cataplexy Pipeline and Future Market Trends - Download the Report Now: https://www.delveinsight.com/report-store/cataplexy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Cataplexy Emerging Drugs

*
FT218: Avadel

FT218 is a GABA B receptor agonist originally developed by Flamel Technologies and is now being advanced by Avadel in Phase 3 clinical trials. The study, which started in June 2020 and is expected to finish by June 2022, enrolls around 250 participants (ClinicalTrials.gov ID: NCT04451668).

*
AXS12: Axome Therapeutics

AXS12 (Reboxetine) is a Phase 2 investigational therapy from Axsome Therapeutics for the treatment of cataplexy, acting as an adrenergic reuptake inhibitor.

Currently, around three key companies are actively developing cataplexy therapies, with Avadel leading the field with candidates in the most advanced stage (Phase III).

Cataplexy Pipeline Therapeutic Assessment

Cataplexy Assessment by Product Type

- Mono

- Combination

- Mono/Combination

Cataplexy By Stage

- Late-stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Cataplexy Assessment by Route of Administration

- Intravenous

- Subcutaneous

- Oral

- Intramuscular

Cataplexy Assessment by Molecule Type

- Monoclonal antibody

- Small molecule

- Peptide

Download the cataplexy Sample Report for Key Insights on the cataplexy Treatment Market and Therapeutics: https://www.delveinsight.com/sample-request/cataplexy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Table of Contents

1. Report Introduction

2. Executive Summary

3. Cataplexy Current Treatment Patterns

4. Cataplexy - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Cataplexy Late-Stage Products (Phase-III)

7. Cataplexy Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Cataplexy Discontinued Products

13. Cataplexy Product Profiles

14. Cataplexy Key Companies

15. Cataplexy Key Products

16. Dormant and Discontinued Products

17. Cataplexy Unmet Needs

18. Cataplexy Future Perspectives

19. Cataplexy Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the cataplexy Pipeline Reports Offerings: https://www.delveinsight.com/report-store/cataplexy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cataplexy-pipeline-analysis-2025-by-delveinsight-avadel-axome-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.